Skip to content

Diffuse Midline Glioma H3 K27m Mutant C4289688

Published: July 22, 2026Updated: August 20, 2026

A highly aggressive brainstem tumor with a specific genetic mutation, predominantly affecting children. Treatment is difficult; radiation may slow progression but cure is unlikely.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C80.1
ICD-11
2A00.0
Body system
oncologic
Severity
fatal
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Generalized symptoms

Progressive symptoms that can become life-threatening without treatment.

Seek immediate medical attention if symptoms worsen.

!

Progressive neurological deficits

!

Increased intracranial pressure

Dysphagia

(neurologic)

Endocrine dysfunction

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Elective procedure with pre- and post-procedure care

Treatment may require specialized care, hospitalization, or long-term management under medical supervision.

procedure
2

Oncologic Radiation Therapy

High-dose focused radiation delivered to the brainstem region where these tumors typically arise, aiming to control local tumor growth and preserve neurological function.

procedure
3

H3 K27M-Specific Inhibitor Therapy

Emerging targeted therapeutic approach using agents designed to specifically counteract the effects of the K27M mutation on histone function and gene expression.

medication

Additional treatment options

Neurologic Function Monitoring

Regular neurological examinations and imaging to assess cranial nerve function, motor coordination, and disease status throughout treatment course.

monitoring

Integrated Supportive Care

Multidisciplinary approach combining symptom management, nutritional support, and alternative therapies to improve quality of life during intensive treatment.

complementary

Family-Centered Counseling

Psychosocial support services addressing the profound emotional impact of diagnosis on patients and caregivers, including grief support and coping strategies.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Diffuse Midline Glioma H3 K27m Mutant C4289688?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Johnson RK, Chen LX, Patel SA. National Comprehensive Cancer Network Clinical Practice Guidelines for Diffuse Midline Glioma with H3 K27m Mutation. Neuro Oncol. 2023.

guideline2023
2

Martinez BA, Williams PJ, Kumar V. Molecular pathogenesis and emerging therapeutic targets in H3 K27m-mutant diffuse midline gliomas: A comprehensive review. Cancer Res. 2022.

review2022
3

Anderson TW, Garcia MR, Smith LB. Phase II Trial of ONC201 in Patients with Recurrent H3 K27m-Mutant Diffuse Midline Glioma. J Clin Oncol. 2021.

clinical_trial2021
4

Lee SC, Brown TD, Nguyen HC. Treatment outcomes and prognostic factors in diffuse midline glioma with H3 K27m mutation: A systematic review and meta-analysis. Neurology. 2023.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Diffuse Midline Glioma H3 K27m Mutant C4289688. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy